Want to see CTOR full AI Analyst Report?
CTOR Stock Chart & Stats
$0.56
>-$0.01(-1.10%)
At close: 4:00 PM EDT
$0.56
>-$0.01(-1.10%)
Day’s Range― - ―
52-Week Range$0.49 - $2.25
Previous Close$0.56
Volume32.62K
Average Volume (3M)56.61K
Market Cap
$69.74M
Enterprise Value$63.79
Total Cash (Recent Filing)$16.56M
Total Debt (Recent Filing)$10.21M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Dec 17, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding92,981,200
10 Day Avg. Volume44,100
30 Day Avg. Volume56,609
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside614.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$20.82M
Bulls Say, Bears Say
Bulls Say
LYMPHIR Commercial ExpansionGrowing institutional adoption, wholesaler orders, formulary inclusion and broad payer coverage provide a durable foundation for LYMPHIR sales growth as access expands across an underserved CTCL market.
Pipeline OptionalityPromising early combination data support development beyond CTCL, potentially expanding LYMPHIR’s addressable market in cancers with limited post-immunotherapy treatment options if larger trials confirm efficacy.
Low Financial LeverageRelatively modest debt reduces immediate solvency pressure and preserves financial flexibility compared with highly leveraged peers, giving the company more capacity to support commercialization and clinical development.
Bears Say
Pre-Revenue Loss ProfileThe absence of an established revenue base leaves the company dependent on successful commercialization and future financing, while widening losses show that operating scale has not yet been achieved.
Worsening Cash BurnIncreasing operating and free-cash-flow deficits raise the likelihood of additional capital needs before product revenue can sustainably fund operations, creating execution and potential dilution risk.
Equity ErosionPersistent losses are reducing the company’s equity base and weakening returns on invested capital. If this pattern continues, financial flexibility may deteriorate even though current leverage remains low.
Citius Oncology News
CTOR FAQ
What was Citius Oncology’s price range in the past 12 months?
Citius Oncology lowest stock price was $0.49 and its highest was $2.25 in the past 12 months.
What is Citius Oncology’s market cap?
Citius Oncology’s market cap is $69.74M.
When is Citius Oncology’s upcoming earnings report date?
Citius Oncology’s upcoming earnings report date is Dec 17, 2026 which is in 112 days.
How were Citius Oncology’s earnings last quarter?
Citius Oncology released its earnings results on Aug 14, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.01.
Is Citius Oncology overvalued?
According to Wall Street analysts Citius Oncology’s price is currently Undervalued.
Does Citius Oncology pay dividends?
Citius Oncology does not currently pay dividends.
What is Citius Oncology’s EPS estimate?
Citius Oncology’s EPS estimate is -0.19.
How many shares outstanding does Citius Oncology have?
Citius Oncology has 92,981,200 shares outstanding.
What happened to Citius Oncology’s price movement after its last earnings report?
Citius Oncology reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went down -18.592%.
Which hedge fund is a major shareholder of Citius Oncology?
Currently, no hedge funds are holding shares in CTOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Citius Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (614.29% Upside)
$4.00 (614.29% Upside)
Blogger Sentiment
Bullish
CTOR Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.23%
Trailing 12-Months
Company Description
Citius Oncology
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
CTOR Stock 12 Month Forecast
Average Price Target
$4.00
▲(614.29% Upside)
Technical Analysis
Ownership Overview
6.58% Insiders
0.79% Mutual Funds
9.36% Other Institutional Investors
82.68% Public Companies and
Individual Investors